GTP Bioways Invests €12M in Two GMP Biopharmaceutical Production Units
GTP Bioways, a CDMO (Contract Development and Manufacturing Organization) specializing in the production of biotherapies and nanotherapies, today announces an investment of €12M ($14M) into two new biopharmaceutical production lines at its site in Toulouse.
The first line will be dedicated to production using microbial systems (bacteria and yeast). With a capacity of 300L, it will be operational in the first quarter of 2023; this will enable GTP Bioways to respond to a rapidly growing market. GTP Bioways will become the only CDMO in France offering a GMP (Good Manufacturing Practices) unit for producing proteins with therapeutic or vaccine-related applications, as well as enzymes for manufacturing mRNA vaccines and synthetic DNA. GTP Bioways’ project was awarded the first prize in the ‘Capacity Building’ call for proposals launched by the French government as part of the France Relance scheme, spearheaded by French investment bank Bpifrance. The microbial production unit project has the support of the Programme d’Investissements d’Avenir, with a €5.9M ($6.9M) backing.
The second pharmaceutical manufacturing unit is designed for the culture of mammalian cells at a scale of 10L. With this second unit, GTP Bioways will be able to produce small batches of proteins and antibodies – varying from a few milligrams to a few grams – for a range of applications. From Q4 of 2022, the unit will be able to manufacture biomolecules for vaccines and RMPU (Raw Materials for Pharmaceutical Use) for the production of cell therapies. This is a fast-growing need and one that very few European CDMOs are currently able to meet. GTP Bioways recently won a contract for the first clinical batches of a nasally administered SARS-CoV-2 vaccine, developed by Tours University.
“We are one of a select group of companies in Europe who are able to provide process development and manufacturing services to biotechnology companies that are working on innovative treatments,” said Eric Devic, CEO of GTP Tech. “The current biomedicine production capacity in France and Europe is not sufficient to meet burgeoning demand. By investing in domestic production lines, we can respond to this situation.”
GTP Bioways’ new production units fit comfortably with the French government’s initiative to bring industrial activity back to France. This was clearly demonstrated with the ‘Grand Défi Bioproduction’ program, launched in 2020, to build a domestic biomedicines industry. Looking beyond the current circumstances with the COVID-19 pandemic, one goal of GTP Bioways is to become a preferred partner for biotechnology companies developing innovative treatments. This would see the company contribute to producing biopharmaceutical products within Europe, specifically in France; thereby helping to strengthen the nation’s ability to meet its own needs for biomedicines.
In order to be able to launch these units rapidly, GTP Bioways is consulting with V3ie, a subsidiary of Validapro, who will help with the building’s engineering and compliance with international regulations. GTP Tech, a member of the GTP Bioways group, with production sites in Toulouse and Labège, intends to double its headcount. It plans to meet the needs of this new site by adding to its production and quality assurance teams, and increasing staff numbers from 45 in 2021, to nearly 100 in 2025.
People In This Post
Companies In This Post
- Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform Read more
- SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices Read more
- Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer Read more
- BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia Read more
- PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs Read more